At a Glance
Therapeutic Area:
Approved Applications:
RotaTeq® is a live, oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis. RotaTeq® was approved by the United States Food and Drug Administration in February 2006, has been approved in seventy other countries and has launched in forty-two of these countries.
Applications In Development:
Acquisition Date:
April 2008
Royalty Seller:



"CHOP will use this money in the continual pursuit of advancing science to benefit children."

Steven M. Altschuler MD, President and Chief Executive Officer, The Children’s Hospital of Philadelphia®.

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.